These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18064698)

  • 1. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
    Cuiné JF; McEvoy CL; Charman WN; Pouton CW; Edwards GA; Benameur H; Porter CJ
    J Pharm Sci; 2008 Feb; 97(2):995-1012. PubMed ID: 18064698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
    Cuiné JF; Charman WN; Pouton CW; Edwards GA; Porter CJ
    Pharm Res; 2007 Apr; 24(4):748-57. PubMed ID: 17372700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.
    Sek L; Boyd BJ; Charman WN; Porter CJ
    J Pharm Pharmacol; 2006 Jun; 58(6):809-20. PubMed ID: 16734982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
    Anby MU; Nguyen TH; Yeap YY; Feeney OM; Williams HD; Benameur H; Pouton CW; Porter CJ
    Mol Pharm; 2014 Nov; 11(11):4069-83. PubMed ID: 25265395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
    Porter CJ; Kaukonen AM; Boyd BJ; Edwards GA; Charman WN
    Pharm Res; 2004 Aug; 21(8):1405-12. PubMed ID: 15359575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.
    Van Speybroeck M; Williams HD; Nguyen TH; Anby MU; Porter CJ; Augustijns P
    Mol Pharm; 2012 Sep; 9(9):2750-60. PubMed ID: 22870936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.
    Anby MU; Williams HD; McIntosh M; Benameur H; Edwards GA; Pouton CW; Porter CJ
    Mol Pharm; 2012 Jul; 9(7):2063-79. PubMed ID: 22656917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion.
    Devraj R; Williams HD; Warren DB; Porter CJ; Pouton CW
    J Pharm Sci; 2014 Apr; 103(4):1050-63. PubMed ID: 24470073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.
    Devalapally H; Silchenko S; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ
    J Pharm Sci; 2013 Oct; 102(10):3808-15. PubMed ID: 23878097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.
    Larsen A; Holm R; Pedersen ML; Müllertz A
    Pharm Res; 2008 Dec; 25(12):2769-77. PubMed ID: 18592356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
    Ramasahayam B; Eedara BB; Kandadi P; Jukanti R; Bandari S
    Drug Dev Ind Pharm; 2015 May; 41(5):753-63. PubMed ID: 24641324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation optimization of self-emulsifying preparations of puerarin through self-emulsifying performances evaluation in vitro and pharmacokinetic studies in vivo.
    Quan DQ; Xu GX
    Yao Xue Xue Bao; 2007 Aug; 42(8):886-91. PubMed ID: 17944241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems.
    Heshmati N; Cheng X; Dapat E; Sassene P; Eisenbrand G; Fricker G; Müllertz A
    J Pharm Pharmacol; 2014 Nov; 66(11):1567-75. PubMed ID: 24961657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH
    Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).
    Thomas N; Holm R; Müllertz A; Rades T
    J Control Release; 2012 May; 160(1):25-32. PubMed ID: 22405903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
    Berthelsen R; Holm R; Jacobsen J; Kristensen J; Abrahamsson B; Müllertz A
    Mol Pharm; 2015 Apr; 12(4):1062-71. PubMed ID: 25679417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.
    McEvoy CL; Trevaskis NL; Edwards GA; Perlman ME; Ambler CM; Mack MC; Brockhurst B; Porter CJ
    Eur J Pharm Biopharm; 2014 Nov; 88(3):973-85. PubMed ID: 25152213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.
    Gursoy RN; Benita S
    Biomed Pharmacother; 2004 Apr; 58(3):173-82. PubMed ID: 15082340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simplified method to screen for in-vivo performance of oral lipid formulations.
    Kilic M; Dressman J
    J Pharm Pharmacol; 2014 May; 66(5):615-23. PubMed ID: 24313318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.